Updated ENZARAD findings show no significant metastasis-free survival benefit with enzalutamide, although patients receiving pelvic lymph node radiation may benefit from intensification.
|Videos|May 28, 2014
A Phase II Trial of PSMA ADC in Taxane-Treated mCRPC
Author(s)Daniel P. Petrylak, MD
Daniel P. Petrylak, MD, discusses a phase II trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (mCRPC).
Advertisement
Clinical Pearls
Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses a phase II trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (mCRPC) presented at the 2014 AUA Annual Meeting.
- Patients with progressive mCRPC progressing after taxane treatment and ECOG PS 0 or 1 were treated with PSMA ADC every 3 weeks.
- Early on, researchers learned that 2.5 mg/kg was too high of a dose and reduced it to 2.3 mg/kg for remaining patients.
- Patients who expressed PSMA on circulating tumor cells and had lack of neuroendocrine markers tended to respond to the antibody complex.
- PSMA ADC was fairly well tolerated. The most common significant adverse events observed were neutropenia and peripheral neuropathy.
Advertisement
Related to this article
The approval expands the combination’s use to patients with androgen pathway modulation–naive or –sensitive disease based on phase 3 TALAPRO-3 findings.
Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.
Lauren Banks, MD, PhD, explains early findings from a pilot study of lifileucel in dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma, including treatment feasibility, safety, and response durability.
Sara Lonardi, MD, discusses the final overall survival analysis of CheckMate-8HW from ESMO 2026 and its implications for first-line MSI-H/dMMR mCRC.
The first-in-class oral RIPTAC molecule JNJ-6143 reached a 75% overall response rate and significant declines in PSA in metastatic castration-resistant prostate cancer.
In an interview, David J. Benjamin, MD, explains the findings on gender makeup of NCCN guideline panels he presented at the 2026 ESMO Congress.
Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders remaining event-free.
Advertisement
Advertisement
Trending on Targeted Onc
1
A New Era in Sarcoma Treatment? Dr Banks on the Potential of TIL Therapy
2
FDA Approves Generic Venetoclax Tablets for CLL/SLL and AML
3
Enzalutamide Fails to Improve Survival in High-Risk Prostate Cancer
4
Neoadjuvant Botensilimab/Balstilimab Shows Activity in Colon Cancer
5